Howard Gurney

机构：Macquarie University · ORCID：0000-0003-0217-5261

发表论文 453 篇 · 总被引 38127 次 · h-index 64

代表论文

• Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial (2025 · European Urology Oncology · 被引 29)
• Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial (2025 · Annals of Oncology · 被引 19)
• Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study (2025 · Annals of Oncology · 被引 16)
• First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial (2025 · European Urology · 被引 13)
• Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients (2025 · ESMO Open · 被引 11)
• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease (2025 · European Urology · 被引 7)